Signifor (Novartis Pharmaceuticals Corporation)


Welcome to the PulseAid listing for the Signifor drug offered from Novartis Pharmaceuticals Corporation. This Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Novartis Pharmaceuticals Corporation
NON-PROPRIETARY NAME: pasireotide
SUBSTANCE NAME: PASIREOTIDE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2012-12-14
END MARKETING DATE: 0000-00-00


Signifor HUMAN PRESCRIPTION DRUG Details:

Item DescriptionSignifor from Novartis Pharmaceuticals Corporation
LABELER NAME: Novartis Pharmaceuticals Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 0.3(mg/mL)
START MARKETING DATE: 2012-12-14
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0078-0633_dd994d84-aaae-413e-9201-2ec5e7d1fcbd
PRODUCT NDC: 0078-0633
APPLICATION NUMBER: NDA200677

Other PASIREOTIDE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Novartis Pharmaceuticals CorporationSignifor